News Release

Field test for dog Leishmania exposure evaluated

A PLOS Neglected Tropical Diseases press release

Peer-Reviewed Publication

PLOS

Field Test for Dog Leishmania Exposure Evaluated

image: "Stepwise description of the rSP03B sero-strip principle: To start the test a buffer is deposited on the sample line (NC membrane) (1). Immediately after applying the buffer, the sample is spotted on the same position (2). Both the buffer and the sample will migrate to the upper part of the strip. The anti-rSP03B Abs present in the sample get captured by the rSP03B Ag coated on the test line (3). The strip is then immediately dipped into the migration buffer solution (4). After which the colloidal gold conjugate mixture gets hydrated and starts migrating upwards together with the moving liquid (5). The anti-dog IgG Ab-gold conjugate binds to the dog IgG Abs on the test line. The colloidal gold control conjugate is captured by the GAC Abs present at the control line (6). NC, Nitrocellulose; Abs, Antibodies; Ag, Antigen; GAC, Goat anti-chicken." view more 

Credit: Willen, et al. (2018)

Dogs infected with Leishmania infantum, a parasite transmitted by the sand fly Phlebotomus perniciosus, are at risk for spreading leishmaniasis infections to humans. A new test, described and evaluated this week in PLOS Neglected Tropical Diseases, provides an easier-than-ever way to test dogs for exposure to P. perniciosus sand flies, and could be used in monitoring the effectiveness of sand fly control efforts.

Canine leishmaniasis (CanL) is a severe multi-systemic disease of dogs that has been reported throughout countries in Latin America, Europe, and Asia. Over 2.5 million dogs are estimated to be infected in southern Europe and the infection is difficult to treat. Control efforts often revolve around targeting sand fly populations. Current ELISA tests, for the presence of a P. perniciosus sand fly saliva protein, are limited to use in a laboratory-- rather than field-- setting.

In the new work, Laura Willen, of Charles University, Czech Republic, and colleagues prepared an immunochromatographic test (ICT) to rapidly screen dogs for the presence of P. perniciosus. The ICT detects the same antibodies against the fly's salivary protein--SP03B--as an existing ELISA test. To optimize the test, the team used 53 laboratory-bred Beagles that had either been exposed or unexposed to 200 P. perniciosus sand flies.

When they compared the ICT to two existing ELISA tests, results were in nearly 100% agreement and the ICT was found to have a sensitivity of 100% and a specificity of 86.79%. Raising the detection limit of the test would lead to a specificity of 96.23% without changing the sensitivity.

"This test is easily operated with no requirements for skilled personnel or specialized equipment," the researchers say. "In order to confirm the field detection accuracy and applicability of the test, further evaluation of canine populations exposed to various frequencies of sand fly bites and validation of the test with whole canine blood is required."

###

In your coverage please use this URL to provide access to the freely available article in PLOS Neglected Tropical Diseases: http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006607

CITATION: Willen L, Mertens P, Volf P (2018) Evaluation of the rSP03B sero-strip, a newly proposed rapid test for canine exposure to Phlebotomus perniciosus, vector of Leishmania infantum. PLOS Neglected Tropical Diseases 12(8): e0006607. https://doi.org/10.1371/journal.pntd.0006607

FUNDING: This project is part of the EuroLeish.Net Training Network and has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement Nº 642609. This work was partially supported by ERD Funds, project CePaViP (CZ.02.1.01/0.0/0.0/16_019/0000759). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

COMPETING INTERESTS: The company, Coris BioConcept, does not have any other affiliations. Pascal Mertens is an employee of Coris BioConcept. He does not hold any share in the company. He is inventor of several patents held by the company without any revenues from these patents.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.